Navigation Links
Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
Date:2/12/2009

RICHMOND, Va., Feb. 12 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals focused on niche markets with unmet medical needs, announced today that it has entered into a definitive agreement with Merck & Co., Inc. whereby Merck, through an affiliate, will purchase all assets related to Insmed's follow-on biologics platform. Under the terms of the agreement, Insmed will receive a total of $130 million for the assets. After fees, taxes and other costs related to the transaction, Insmed expects net proceeds of approximately $123 million as a result of this agreement.

As part of this transaction, Insmed will receive initial payments of up to $10 million for Insmed's lead follow-on-biologic candidates and the remaining balance upon closing of the transaction, which is targeted for March 31, 2009. These initial payments will allow the Company to maintain its normal business operations throughout the closing period without the need for dilutive financing.

Insmed's follow-on biologics assets include INS-19 and INS-20, whose development and commercial rights will now belong to Merck, as well as the Boulder, Colorado-based manufacturing facility. Merck intends to assume the facility's lease and ownership of all the equipment in the building. In addition, upon closing of the transaction, Merck intends to offer positions to employees of the Boulder facility. Insmed will retain its Richmond, VA corporate office, which houses its Clinical, Regulatory, Finance, and Administrative functions, in support of the continuing IPLEX(TM) program.

"We have long maintained that our follow-on biologics assets hold substantial value, and this agreement with Merck, one of the largest pharmaceutical companies in the world, is a testament to that value," said Dr
'/>"/>

SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
2. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
3. NASDAQs Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmeds Compliance Date to March 20, 2009
4. Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
5. Insmed to Seek Shareholder Approval for Reverse Split
6. Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
7. Insmed to Present at Biosimilars 2008 Conference
8. Insmed to Present at BioPharm Asia 2008 Conference
9. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
10. Insmed CEO to Present at Drug Discovery & Development Conference
11. Insmed to Host Second Quarter 2008 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... ARPN) today reported that it has submitted a ... intravenous iclaprim for the treatment of,complicated Skin and ... and,Drug Administration (FDA). Arpida has requested a Priority ... a synthetic diaminopyrimidine which,exhibits a rapidly bactericidal action ...
... the National Institute of Standards and Technology (NIST) have ... the microelectronics of today built from semiconductor compounds and ... molecules. In an upcoming paper in the Journal of ... a single layer of organic molecules can be assembled ...
... Inverness Medical,Innovations, Inc. (Amex: IMA ), a ... the consumer and professional markets, announced,today that as ... worldwide,operations for the purpose of lowering operating costs ... close two facilities in the San,Francisco area which ...
Cached Biology Technology:Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections 2Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections 3NIST team proves bridge from conventional to molecular electronics possible 2Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities 2Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities 3
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, a ... Internet of Things (IoT), today announced the appointment of ... operating officer. Previously a strategic advisor to the firm, ... operations. Mr. Traynor is based out of the C-Labs ... reports to Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... WASHINGTON , Nov. 18, 2014  The ... Security Industry Association today jointly announce the formation ... and release of its Identity and Biometric ... (Framework). The Framework received official support from BORDERPOL, ... governments to improve and provide expertise regarding border ...
(Date:11/18/2014)... Nov. 17, 2014 The Parenteral Drug Association (PDA) ... agencies will speak and at least seven more will participate ... the Omni Shoreham Hotel in Washington D.C. ... to have significant support from the regulatory agencies in ... in our effort to help advance the use ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... BEDFORD, Mass., April 1, 2011 Aware, Inc. (NASDAQ: ... for the telecommunications and biometrics industries, today announced that Edmund ... and Chief Executive Officer and director of the board of ... Moberg, CFO and Kevin T. Russell, General Counsel have been ...
... for Engineering in Medicine (CEM) -- a bioengineering research ... Teaching Hospital -- has announced it will reconvene its ... organizer Horizon House Ltd.  The event, BioMethods Boston, will ... and expects to draw over 400 senior researchers from ...
... Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and ... from human amniotic membrane, announced today the nation-wide launch ... specifically processed to offer a wide variety of wound ... the hiring of Frank Burrows as its Vice President ...
Cached Biology News:Aware, Inc. Announces Resignation of Chief Executive Officer 2Aware, Inc. Announces Resignation of Chief Executive Officer 3Massachusetts General Hospital Center Reignites Methods in Bioengineering Conference 2MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 2MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 3MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 4
... 100 IS System is a compact analysis system ... lasers, optics, fluidics, a controller, advanced digital signal ... compact lab analysis system includes the Luminex 100, ... has a DMF file at the FDA, and ...
... for routine binary separations. Excellent detection is ... UV-Visible variable wavelength detector. Ultra-fine control of ... two highly accurate and precise, high pressure dual ... Chromatograms may be plotted on a printer or ...
... cultured in Minimum Essential Medium (Eagle) with 2 ... of growth. In order to keep the ... in acetone-methanol. The cells are arrayed on ... each wells surface specifically treated to enhance cellular ...
... were cultured in RPMI 1640 with 2 mM ... growth. In order to keep the antigens ... acetone-methanol. The cells are arrayed on a ... wells surface specifically treated to enhance cellular attachment ...
Biology Products: